Please login to the form below
Nasdaq
This page shows the latest Nasdaq news and features for those working in and with pharma, biotech and healthcare.
AZ sells stake in Moderna for around $1.2bn
The Massachusetts, US-based company was first listed on Nasdaq in 2018 at $23 per share, surging in value in 2020 after it started developing its two-dose COVID-19 vaccine.
Latest news
-
Aimmune’s Palforzia is first peanut allergy drug cleared in US
Shares in the Nasdaq-listed biotech have spiked. The first drug to treat peanut allergy, Aimmune’s Palforzia, has been approved by the US Food and Drug Administration for use in ... children, causing shares in the Nasdaq-listed biotech to spike.
-
Intec battered as Novartis ducks out of Accordion collaboration
Novartis has said the programme no longer fits with its “mid- to long-term strategic goals”, according to Intec, which saw its Nasdaq-listed shares fall by more than 12% after
-
Y-mAbs files breakthrough neuroblastoma drug in US
The filing of naxitamab in neuroblastoma is a key milestone for the biotech and comes after a busy couple of years punctuated by a listing on the Nasdaq that raised $96m,
-
Sanofi settles Lemtrada dispute with Genzyme investors for $315m
When Sanofi tabled its bid for Genzyme the two companies couldn’t agree a value for Lemtrada, so Sanofi agreed to add one Nasdaq-listed CVR – linked to Lemtrada – for every ... The case has finally come to a close, with Sanofi agreeing to make the
-
France’s Innate Pharma eyes $100m Nasdaq IPO
Would help fund development of antibody-based immunotherapies. Innate Pharma is seeking to raise $100m via a public listing on the Nasdaq that would help fund development of its antibody-based ... Both are thought to have potential in solid tumours.
More from news
Approximately 4 fully matching, plus 72 partially matching documents found.
Latest Intelligence
-
Building European biotech firms to rival those of the US
European biotechs still rely on the US for IPOs. A significant missing piece of the finance puzzle for European biotechs is that they have to launch on the US Nasdaq exchange
-
European biotech: a new generation of leaders emerges
In April last year, it achieved a very successful IPO on the US Nasdaq, generating $208m thanks to investor belief in its cancer-focused antibody-based pipeline. ... In June, the Danish company raised a record-breaking $506m with an initial public
-
Biopharma's Future: Made in China
In terms of biotech funding, the emergence of Hong Kong’s stock market could potentially make Europe’s Euronext and AIM markets, already dwarfed by the NASDAQ, irrelevant.
-
Bluebird Bio: on the cusp of a gene therapy revolution
The company launched its IPO on the Nasdaq in 2013, and those years of ups and downs mean it is well known to investors – if not yet a household name.
-
Revenue down the back of the beanbag
Everyone wants to have a role in a winning team, regardless if that team is a Nasdaq listed company or a ten-person start-up.
More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.
Latest appointments
-
New finance head for Xenon
listing on Nasdaq in 2010.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Syneos Health®
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Rare diseases: not so rare after all
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
